Drug Profile
Ipilimumab biosimilar - Innovent Biologics
Alternative Names: Anti-CTLA-4 antibody - Innovent Biologics; IBI-310Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Innovent Biologics
- Developer Innovent Biologics; Peking University
- Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Acral lentiginous melanoma; Colorectal cancer; Liver cancer
- Phase II Cervical cancer; Neuroendocrine tumours
- Phase I/II Biliary cancer; Gastric cancer; Nasopharyngeal cancer
- Phase I Non-small cell lung cancer
- Clinical Phase Unknown Renal cell carcinoma
- No development reported Solid tumours
Most Recent Events
- 27 Mar 2024 Phase-III clinical trials in Colorectal cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
- 20 Nov 2023 Innovent Biologics completes a phase-II trial in Cervical cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04590599)
- 20 Oct 2023 Safety and efficacy data from a phase I/II trial in Gastric cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)